Functional analysis of 13GBAmutant alleles identified in Gaucher disease patients: Pathogenic changes and “modifier” polymorphisms
Open Access
- 30 April 2004
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 23 (6) , 567-575
- https://doi.org/10.1002/humu.20043
Abstract
Gaucher disease, the most prevalent sphingolipidosis, is caused by the deficient activity of acid β‐glucosidase, mainly due to mutations in the GBA gene. Over 200 mutations have been identified worldwide, more than 25 of which were in Spanish patients. In order to demonstrate causality for Gaucher disease, some of them: c.662C>T (p.P182L), c.680A>G (p.N188S), c.886C>T (p.R257X), c.1054T>C (p.Y313H), c.1093G>A (p.E326K), c.1289C>T (p.P391L), c.1292A>T (p.N392I), c.1322T>C (p.I402T), and the double mutants [c.680A>G; c.1093G>A] ([p.N188S; p.E326K]) and [c.1448T>C; c.1093G>A] ([p.L444P; p.E326K]), were expressed in Sf9 cells using a baculovirus expression system. Other well‐established Gaucher disease mutations, namely c.1226A>G (p.N370S), c.1342G>C (p.D409H), and c.1448T>C (p.L444P), were also expressed for comparison. The levels of residual acid β‐glucosidase activity of the mutant enzymes produced by the cDNAs carrying alleles c.662C>T (p.P182L), c.886C>T (p.R257X), c.1054T>C (p.Y313H), c.1289C>T (p.P391L), and c.1292A>T (p.N392I) were negligible. The c.1226A>G (p.N370S), c.1322T>C (p.I402T), c.1342G>C (p.D409H), c.1448T>C (p.L444P), and [c.1448T>C; c.1093G>A] ([p.L444P; p.E326K]) alleles produced enzymes with levels ranging from 6 to 14% of the wild‐type. The three remaining alleles, c.680A>G (p.N188S), c.1093G>A (p.E326K), and [c.680A>G; c.1093G>A] ([p.N188S; p.E326K]), showed higher activity (66.6, 42.7, and 23.2%, respectively). Expression studies revealed that the c.1093G>A (p.E326K) change, which was never found alone in a Gaucher disease‐causing allele, when found in a double mutant such as [c.680A>G; c.1093G>A] ([p.N188S; p.E326K]) and [c.1448T>C; c.1093G>A] ([p.L444P; p.E326K]), decreases activity compared to the activity found for the other mutation alone. These results suggest that c.1093G>A (p.E326K) should be considered a “modifier variant” rather than a neutral polymorphism, as previously considered. Mutation c.680A>G (p.N188S), which produces a mutant enzyme with the highest level of activity, is probably a very mild mutation or another “modifier variant.” Hum Mutat 23:567–575, 2004.Keywords
Funding Information
- Genzyme
- CICYT (SAF 2000-0200)
- fundacio marato de TV3 (98-1220/1221)
- FIS (Redes Temáticas) (G03/054)
This publication has 26 references indexed in Scilit:
- Transient expression of wild-type and mutant glucocerebrosidases in hybrid vaccinia expression systemEuropean Journal of Human Genetics, 2003
- Human Gene Mutation Database (HGMD®): 2003 updateHuman Mutation, 2003
- The E326K mutation and Gaucher disease: mutation or polymorphism?Clinical Genetics, 2002
- Identification and Characterization of a Novel Mutation c.1090G>T (G325W) and Nine Common Mutant Alleles Leading to Gaucher Disease in Spanish PatientsBlood Cells, Molecules, and Diseases, 2001
- Gaucher disease: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patientsEuropean Journal of Human Genetics, 2000
- Non–pseudogene-derived complex acid β-glucosidase mutations causing mild type 1 and severe type 2 Gaucher diseaseJournal of Clinical Investigation, 1999
- Expression of Mutated Glucocerebrosidase Alleles in Human CellsHuman Molecular Genetics, 1997
- Neuronopathic and non‐neuronopathic presentation of Gaucher disease in patients with the third most common mutation (D409H) in SpainJournal of Inherited Metabolic Disease, 1996
- Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.Journal of Medical Genetics, 1995
- Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.Journal of Clinical Investigation, 1993